Price Target Changed • 1h
Price target decreased by 9.8% to zł44.32 Down from zł49.15, the current price target is an average from 6 analysts. New target price is 76% above last closing price of zł25.15. Stock is down 30% over the past year. The company is forecast to post earnings per share of zł0.64 for next year compared to zł0.044 last year. Announcement • Jun 01
Selvita S.A., Annual General Meeting, Jun 24, 2026 Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time. Reported Earnings • May 26
First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025) First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 06
Full year 2025 earnings released: EPS: zł0.044 (vs zł0.33 loss in FY 2024) Full year 2025 results: EPS: zł0.044 (up from zł0.33 loss in FY 2024). Revenue: zł371.1m (up 7.3% from FY 2024). Net income: zł813.0k (up zł6.91m from FY 2024). Profit margin: 0.2% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Price Target Changed • Nov 26
Price target increased by 9.1% to zł49.90 Up from zł45.73, the current price target is an average from 6 analysts. New target price is 7.5% above last closing price of zł46.40. Stock is down 8.7% over the past year. The company is forecast to post a net loss per share of zł0.27 next year compared to a net loss per share of zł0.33 last year. Reported Earnings • Nov 24
Third quarter 2025 earnings released: zł0.05 loss per share (vs zł0.13 profit in 3Q 2024) Third quarter 2025 results: zł0.05 loss per share (down from zł0.13 profit in 3Q 2024). Revenue: zł89.5m (flat on 3Q 2024). Net loss: zł936.0k (down 139% from profit in 3Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Announcement • Nov 15
Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025 Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025 Reported Earnings • Sep 19
Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.55 loss in 2Q 2024) Second quarter 2025 results: zł0.25 loss per share (improved from zł0.55 loss in 2Q 2024). Revenue: zł95.0m (up 17% from 2Q 2024). Net loss: zł4.61m (loss narrowed 54% from 2Q 2024). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Price Target Changed • Sep 19
Price target decreased by 7.7% to zł45.73 Down from zł49.55, the current price target is an average from 6 analysts. New target price is 22% above last closing price of zł37.60. Stock is down 40% over the past year. The company is forecast to post a net loss per share of zł0.30 next year compared to a net loss per share of zł0.33 last year. Announcement • Aug 21
Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025 Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025 Price Target Changed • Jul 22
Price target decreased by 9.1% to zł50.66 Down from zł55.75, the current price target is an average from 5 analysts. New target price is 62% above last closing price of zł31.30. Stock is down 52% over the past year. The company is forecast to post earnings per share of zł1.10 next year compared to a net loss per share of zł0.33 last year. New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 23
First quarter 2025 earnings released: zł0.05 loss per share (vs zł0.12 loss in 1Q 2024) First quarter 2025 results: zł0.05 loss per share (improved from zł0.12 loss in 1Q 2024). Revenue: zł91.2m (up 18% from 1Q 2024). Net loss: zł986.0k (loss narrowed 54% from 1Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 28
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: zł0.003 loss per share (down from zł3.81 profit in FY 2023). Revenue: zł345.8m (down 1.7% from FY 2023). Net loss: zł6.10m (down 109% from profit in FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 20
Price target decreased by 10% to zł55.75 Down from zł62.15, the current price target is an average from 6 analysts. New target price is 13% above last closing price of zł49.35. Stock is down 15% over the past year. The company is forecast to post a net loss per share of zł0.54 compared to earnings per share of zł3.81 last year. Buy Or Sell Opportunity • Jan 22
Now 20% overvalued Over the last 90 days, the stock has fallen 17% to zł46.90. The fair value is estimated to be zł38.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.5% over the last 3 years. Earnings per share has grown by 57%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to decline by 23% in the next 2 years. Announcement • Dec 11
Selvita Strengthens Management Structure in Sales and Drug Development Segment Selvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets. Price Target Changed • Dec 09
Price target decreased by 10% to zł62.15 Down from zł69.23, the current price target is an average from 6 analysts. New target price is 16% above last closing price of zł53.40. Stock is down 12% over the past year. The company is forecast to post a net loss per share of zł0.63 compared to earnings per share of zł3.81 last year. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 22
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: zł89.5m (up 6.4% from 3Q 2023). Net income: zł2.42m (up zł6.70m from 3Q 2023). Profit margin: 2.7% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 26
Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023) Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Sep 05
Now 21% overvalued Over the last 90 days, the stock has fallen 1.8% to zł64.80. The fair value is estimated to be zł53.49, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 53%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Reported Earnings • May 23
First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023) First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • May 08
Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o. Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day.
Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024. Reported Earnings • Mar 31
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Mar 19
Selvita S.A. Launches Biologic Drug Discovery and Development Services Selvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market. Price Target Changed • Feb 01
Price target decreased by 15% to zł70.18 Down from zł82.93, the current price target is an average from 5 analysts. New target price is 19% above last closing price of zł59.20. Stock is down 30% over the past year. The company is forecast to post earnings per share of zł0.57 for next year compared to zł1.65 last year. Reported Earnings • Nov 21
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: zł84.1m (down 23% from 3Q 2022). Net loss: zł4.27m (down 148% from profit in 3Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Reported Earnings • Jun 04
First quarter 2023 earnings released First quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Announcement • Jun 02
Selvita S.A., Annual General Meeting, Jun 27, 2023 Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time. Price Target Changed • May 23
Price target decreased by 11% to zł86.10 Down from zł96.34, the current price target is an average from 5 analysts. New target price is 11% above last closing price of zł77.50. Stock is up 2.8% over the past year. The company is forecast to post earnings per share of zł1.67 for next year compared to zł1.65 last year. Buying Opportunity • Nov 24
Now 21% undervalued Over the last 90 days, the stock is up 3.5%. The fair value is estimated to be zł102, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 64% over the last 3 years. Earnings per share has declined by 17%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings is also forecast to grow by 32% per annum over the same time period. Reported Earnings • Sep 17
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Buying Opportunity • Aug 18
Now 21% undervalued Over the last 90 days, the stock is up 3.9%. The fair value is estimated to be zł101, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has declined by 4.6%. Revenue is forecast to grow by 48% in 2 years. Earnings is forecast to grow by 337% in the next 2 years. Buying Opportunity • Jun 08
Now 22% undervalued Over the last 90 days, the stock is up 7.3%. The fair value is estimated to be zł91.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 4.8%. Revenue is forecast to grow by 47% in 2 years. Earnings is forecast to grow by 323% in the next 2 years. Reported Earnings • Jun 02
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 8.1%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Poland. Reported Earnings • Apr 05
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.6%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Poland. Buying Opportunity • Mar 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be zł82.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years. Buying Opportunity • Mar 01
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be zł83.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years. Reported Earnings • Nov 25
Third quarter 2021 earnings: Revenues exceed analyst expectations Third quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Poland. Reported Earnings • Sep 23
Second quarter 2021 earnings released The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020). Reported Earnings • May 30
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improved over the past week After last week's 16% share price gain to zł74.00, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 163% over the past year. Is New 90 Day High Low • Mar 11
New 90-day high: zł63.20 The company is up 35% from its price of zł46.80 on 11 December 2020. The Polish market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł28.31 per share. Is New 90 Day High Low • Jan 19
New 90-day high: zł58.60 The company is up 39% from its price of zł42.20 on 21 October 2020. The Polish market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 13% over the same period. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 15% share price gain to zł57.60, the stock is trading at a trailing P/E ratio of 23.6x, up from the previous P/E ratio of 20.5x. This compares to an average P/E of 61x in the Life Sciences industry in Europe. Total returns to shareholders over the past year are 136%. Is New 90 Day High Low • Dec 30
New 90-day high: zł49.30 The company is up 19% from its price of zł41.40 on 01 October 2020. The Polish market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 9.0% over the same period. Reported Earnings • Nov 26
Third quarter 2020 earnings released: EPS zł0.24 The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: zł37.3m (up 39% from 3Q 2019). Net income: zł4.41m (up 39% from 3Q 2019). Profit margin: 12% (in line with 3Q 2019). Is New 90 Day High Low • Oct 30
New 90-day low: zł39.70 The company is down 8.0% from its price of zł43.20 on 31 July 2020. The Polish market is down 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 9.0% over the same period. Is New 90 Day High Low • Oct 01
New 90-day low: zł41.40 The company is down 14% from its price of zł48.00 on 03 July 2020. The Polish market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 19% over the same period. 
